These last few years, clinical trials on the use of psychedelics such as MDMA, LSD or psilocybin as treatments for various mental health conditions have increased significantly. For clinical trials to run, however, participants are needed.
At first glance, it may seem easy to enroll individuals for trials given that quite a number of people suffer from mental conditions such as depression and anxiety. However, for an individual to be enrolled into a clinical trial, they must meet the stipulated inclusion criteria in order to be eligible. Below are steps on how one can enroll in a psychedelic clinical trial.
Receive your diagnosis
You must have the condition which a particular clinical trial is attempting to treat. For instance, if a clinical trial is attempting to treat major depressive disorder using psychedelics such as MDMA, ketamine and psilocybin, then the participants must first receive a diagnosis for the condition in order for the treatment data collected to be accurate.
It should be noted that you still have a chance of participating in a clinical trial even if you haven’t been diagnosed with a mental health condition. Most phase I trials usually test drug safety on healthy individuals before moving to phase II and III trials where they test a drug’s effectiveness.
Find trials in your area
It may be challenging to find a clinical trial that’s recruiting participants, especially if you live far from major city centers. If you’d like to take part in a trial, consider searching online for organizations that are recruiting participants using sites such as ClinicalTrial.gov.
Meet every requirement listed
Once you’ve found a clinical trial near you that’s attempting to treat a condition with which you’ve been diagnosed, it is important to make sure that you meet all of the requirements listed in the eligibility criteria. Additionally, you should ensure that you meet none of the exclusion criteria, because this may disqualify you from taking part in the trial.
Fill out an application
After ensuring that you’re eligible, apply for said trial. This usually involves reaching out to parties in charge of recruiting.
Complete the screening process
Once you’ve established contact, researchers will ensure that you’re a good fit for the trial and that you meet the eligibility criteria. During this step, you may undergo mental and physical examination as well as be informed of the possible risks involved, your responsibilities and other important information.
After this, you then give consent by signing a consent form. One should keep in mind that you can still leave the trial, even if you’ve given your consent at one point.
Given that various biopharmaceutical companies such as Silo Pharma Inc. (OTCQB: SILO) have interest in the therapeutic potential of psychedelics, it may no longer be difficult to identify studies that will be conducted near you and enroll as a study subject.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.